A randomised double-blind placebo-controlled cancer prevention trial with an estimated duration of 5 years and with 52,000 subjects recruited from the general populations of the UK, Denmark, Sweden, Finland and the United States

ISRCTN ISRCTN64336220
DOI https://doi.org/10.1186/ISRCTN64336220
Protocol serial number PRECISE
Sponsor Cancer Research UK (CRUK) (UK)
Funder Cancer Research UK (UK)
Submission date
01/07/2001
Registration date
01/07/2001
Last edited
15/11/2013
Recruitment status
Stopped
Overall study status
Stopped
Condition category
Cancer
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr - -
Scientific

UKCCCR Register Co-ordinator
MRC Clinical Trials Unit
222 Euston Road
London
NW1 2DA
United Kingdom

Study information

Primary study designInterventional
Study designRandomised double-blind placebo-controlled
Secondary study designRandomised controlled trial
Scientific title
Study objectivesNot provided at time of registration

Added as of 27/03/2009: Please note that this trial never started due to lack of funding.
Ethics approval(s)Not provided at time of registration
Health condition(s) or problem(s) studiedMultiple cancer sites
InterventionFour treatment groups:
1. Placebo
2. 100 micrograms selenium/day
3. 200 micrograms selenium/day
4. 300 micrograms selenium/day
Intervention typeOther
Primary outcome measure(s)

Not provided at time of registration

Key secondary outcome measure(s)

Not provided at time of registration

Completion date29/06/2001
Reason abandoned (if study stopped)Lack of funding/sponsorship

Eligibility

Participant type(s)Patient
Age groupAdult
SexAll
Target sample size at registration52000
Key inclusion criteriaAll those aged between 60 and 74 years are eligible.
Key exclusion criteria1. Southwest Oncology Group (SWOG) performance status score of greater then 1 or equivalent
2. Active liver or kidney disease
3. Prior diagnosis of cancer
4. Diagnosed Human Immunodeficiency Virus (HIV) infection
5. Disminished mental capacity
6. Taking 50 micrograms/day or more of selenium supplements
Date of first enrolment01/01/1995
Date of final enrolment29/06/2001

Locations

Countries of recruitment

  • United Kingdom
  • England
  • Denmark
  • Finland
  • Sweden
  • United States of America

Study participating centre

UKCCCR Register Co-ordinator
London
NW1 2DA
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to shareNo
IPD sharing plan summary
IPD sharing plan